Median follow-up was about 6.7 years in both groups. The 5-year OS was 79.8% in the surgery group and 78% in the RFA group. Adjustment for baseline differences did not change the results. The 5-year ...

From clinical trials to AI-powered drug discovery, pharmaceutical companies are under pressure to unlock the full value of their data - without compromising security, privacy, or compliance.This eBook ...

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

A new AI software aims to identify people at risk of dementia – during high street eye exams. Data scientists and clinical ...

Elix is a Japan-based AI drug discovery company with a mission to "Rethinking drug discovery," providing services to ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to ...

Data suggest that OSA diagnoses were associated with an increased risk for physical and psychological problems in active-duty ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.